Medical device company Penumbra (NYSE:PEN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 22.1% year on ...

The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion. Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, ...

Publicly traded global medical device company Penumbra expanded its portfolio to include virtual reality offerings through its REAL Immersive System in 2019. The system is designed to help clinicians ...

Penumbra executives might have gotten a bit ahead of themselves when providing 2024 guidance earlier in the year, CEO Adam Elsesser admitted during a recent earnings call. "And that's on me personally ...

Penumbra offers compelling growth in mechanical thrombectomy, with strong recent results and expanding addressable markets in pulmonary embolism and neurovascular. PEN’s STORM-PE and CLOSABLE studies ...

Boston Scientific (NYSE:BSX) announced a Class I recall of its AXIOS Stent and Electrocautery-Enhanced Delivery Systems due ...

A deep dive into the rocky history of the JET 7 reperfusion catheter with Xtra Flex Technology, published this week in JAMA Internal Medicine, is aiming to renew discussions on medical device safety.

Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot ...